Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3

3(50.0%)

N/A

1(16.7%)

Phase 1

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 3(3)

N/A(1)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06472245Phase 3Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Role: collaborator

NCT06381024Not ApplicableCompleted

A Study of Telemonitoring in Cancer Patients

Role: collaborator

NCT05307874Phase 1Completed

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

Role: collaborator

NCT06465472Phase 3Not Yet Recruiting

Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3

Role: collaborator

NCT03798899Phase 4Completed

Efficacy and Safety of Penthrox® Combined With a Standard Analgesia (SoC) in Adult Patients Admitted to the Emergency Department With Moderate to Severe Pain Associated With Trauma

Role: collaborator

NCT03362684Phase 3Completed

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

Role: collaborator

All 6 trials loaded